Bloomberg Talks

Episode: Pfizer CEO Albert Bourla Talks Weight Loss Drugs

Date: January 12, 2026
Host: Bloomberg
Guest: Albert Bourla (Pfizer CEO)

Overview

This episode features an in-depth conversation with Pfizer CEO Albert Bourla, focusing on the company’s strategic outlook amidst patent expirations, its ambitious ventures into the obesity drug market, ongoing R&D investments, and the landscape-shifting political agreements on drug pricing. Bourla provides candid insights on maintaining investor confidence, recent deals, and how Pfizer is positioning itself for future growth, especially around its highly anticipated weight loss drug platforms.

Key Discussion Points and Insights

Navigating Patent Expiry and Growth Prospects (00:38–01:16)

• Bourla outlines Pfizer’s multi-year plan for managing anticipated patent expirations (notably in 2028), highlighting acquisitions in obesity (Matsara), oncology, and migraine treatments.
• Despite a lull in top-line growth ahead of 2028, the expectation is for "exponential growth" in sales post-patent cliff.
• Key metric: $10B in sales for the year, with double-digit growth projected for years 2025 and 2026.

Keeping Investors Engaged Amidst Uncertainty (01:16–02:55)

• With no plans for near-term buybacks and a GLP-1 drug not expected on the market until 2028, Pfizer is focusing on upcoming "catalysts" to maintain investor interest.
  • Clinical Milestones: Two major readouts for obesity drugs in the Matsara portfolio scheduled for 2026:
    • Ultra-long monthly dosing study (first half of the year)
    • GLP-1 and amylin combination study
  • Other highlights: A myeloma drug (Lrexview) with potential to double target population and a Lyme disease vaccine entering a “first-of-its-kind” phase.
• Bourla emphasizes that Pfizer’s current stock multiple is low and anticipates movement toward, and possibly beyond, the industry average as these catalysts materialize.

"Investors want to see catalysts and this is a year that is very rich in catalysts... Investors are watching all of that."
— Albert Bourla (01:39)

The Obesity Market: Matsara Acquisition & Differentiation (02:55–04:20)

• After outbidding Novo Nordisk, Pfizer’s obesity play centers on Matsara’s once-monthly injectable therapy.
  • Competitive Edges:
    • Monthly dosing improves patient convenience, manufacturing, and cost profiles.
    • Combination of amylin with GLP-1 agonists aims to deliver "better weight loss...and better tolerability," addressing current limitations in GLP-1 therapies.
    • Oral peptide portfolio also in development.
• Bourla references Pfizer’s commercial strengths with consumer-driven products (evoking Viagra’s market impact).

“One, it is the monthly dosing that’s a very clear differentiation... The second is the combination between Amylin and PD L1... not only will be a monthly but hopefully can deliver better weight loss... and better tolerability, which are the two things that are the Achilles heels of the GLP ones right now.”
— Albert Bourla (03:16)

Pfizer’s M&A Strategy and Portfolio Satisfaction (04:20–05:00)

• Of the $15B earmarked for acquisitions, almost $10B has been invested, notably in oncology and obesity.
• Bourla expresses satisfaction with the current portfolio, but keeps ~$5B uncommitted, seeking further strategic assets.

“We plan to invest them. We don't have to invest them, but we're trying to make sure that we will find the right assets as we found with our oncology and obesity acquisitions.”
— Albert Bourla (04:40)

R&D Investment Focus (05:00–05:43)

• $500M in cost savings being reinvested, primarily into R&D.
  • Oncology portfolio currently absorbs ~40% of R&D spend and will likely increase.
  • Obesity research is rapidly scaling: 15+ ongoing studies, with 10 pivotal phase 3 trials.
• Bourla frames this as a sign of confidence in their new obesity molecules.

Political Landscape and Drug Pricing Deals (05:43–07:34)

• Pfizer was the first major drugmaker to reach a pricing deal with President Trump’s administration, setting a template now adopted by at least 17 other companies.
• Bourla is “optimistic that it’s behind us” regarding tariff threats and unsustainable pricing tensions, noting productive White House engagement and progress, especially with the UK government.
• Comparison of frequent, close communication with both Trump and Biden administrations during critical periods (COVID response and pricing negotiations).

“We have created very solid agreements and we have created a political environment that there is good willingness from the White House to respect and actually to help us with pricing outside the US...”
— Albert Bourla (06:05)

“I was very close with the Trump administration in the beginning. I was very close with the Biden administration because we had to work together with COVID. With Trump, we work together to develop the vaccine...with Biden was the period to scale it up, to invest it.”
— Albert Bourla (07:05)

Advice for Pharma CEOs Engaging with Policymakers (07:34–08:25)

• Bourla urges industry peers to proactively engage with policymakers, emphasizing that Pfizer’s collaborative approach has resolved key pricing issues for new drugs across rich countries.

“Engage, engage and discuss. I’m very proud of what we did. I think what we did opens the way for the entire industry...puts to bed an issue that was not sustainable.”
— Albert Bourla (07:48)

Notable Quotes

• Catalysts for Investors:
  “This is a year that is very rich in catalysts...Investors are watching all of that.” (Albert Bourla, 01:39)

• Matsara’s Differentiation:
  “Monthly dosing...creates significant advantages not only in patient experience but also in production and cost of goods.” (Albert Bourla, 03:16)

• M&A Strategy:
  “We plan to invest them. We don't have to invest them, but we're trying to make sure that we will find the right assets...” (Albert Bourla, 04:40)

• Government Engagement:
  “We have created very solid agreements and...a political environment that there is good willingness from the White House...” (Albert Bourla, 06:05)
  “Engage, engage and discuss...what we did opens the way for the entire industry.” (Albert Bourla, 07:48)

Timestamps for Important Segments

• 00:38 – Bourla on patent expirations and future growth
• 01:39 – Investor catalysts: obesity and oncology readouts
• 03:16 – Obesity drug (Matsara) differentiation and market impact
• 04:40 – Assessment of current M&A portfolio strategy
• 05:18 – R&D reinvestment priorities
• 05:43 – Political landscape and U.S./international drug pricing
• 07:05 – Working with Trump and Biden administrations
• 07:48 – Advice to other CEOs on regulatory engagement

Memorable Moments

• Bourla highlighting the commercial similarities between potential obesity blockbusters and Viagra (03:16)
• The open, almost promotional advice to other pharma company leaders to “engage and discuss” drug pricing deals with governments (07:48)
• The optimistic outlook about “putting to bed” global pricing disparities through international cooperation (06:05–07:48)

This episode provides a comprehensive look at how Pfizer is navigating industry headwinds and seizing new opportunities. Bourla’s direct and pragmatic tone, alongside frequent references to both investor priorities and political realities, highlights the multi-dimensional strategy Pfizer is taking as it aims to lead the next era of global pharmaceuticals.